X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GSK PHARMA ALKEM LABORATORIES/
GSK PHARMA
 
P/E (TTM) x - 67.5 - View Chart
P/BV x 7.0 13.6 51.8% View Chart
Dividend Yield % 0.6 2.1 29.0%  

Financials

 ALKEM LABORATORIES   GSK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
GSK PHARMA
Mar-18
ALKEM LABORATORIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5892,760 57.6%   
Low Rs1,2322,040 60.4%   
Sales per share (Unadj.) Rs417.5339.0 123.1%  
Earnings per share (Unadj.) Rs56.341.4 135.9%  
Cash flow per share (Unadj.) Rs64.745.9 141.0%  
Dividends per share (Unadj.) Rs12.7035.00 36.3%  
Dividend yield (eoy) %0.91.5 61.7%  
Book value per share (Unadj.) Rs292.9242.9 120.6%  
Shares outstanding (eoy) m119.5784.70 141.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.47.1 47.7%   
Avg P/E ratio x25.157.9 43.2%  
P/CF ratio (eoy) x21.852.3 41.7%  
Price / Book Value ratio x4.89.9 48.7%  
Dividend payout %22.684.5 26.7%   
Avg Mkt Cap Rs m168,653203,280 83.0%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1715,234 175.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,91528,715 173.8%  
Other income Rs m1,645545 301.6%   
Total revenues Rs m51,56129,260 176.2%   
Gross profit Rs m8,4825,059 167.7%  
Depreciation Rs m1,006380 264.7%   
Interest Rs m6712 33,530.0%   
Profit before tax Rs m8,4515,222 161.8%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m1,6061,892 84.9%   
Profit after tax Rs m6,7313,508 191.9%  
Gross profit margin %17.017.6 96.5%  
Effective tax rate %19.036.2 52.5%   
Net profit margin %13.512.2 110.4%  
BALANCE SHEET DATA
Current assets Rs m27,06221,815 124.1%   
Current liabilities Rs m15,32415,999 95.8%   
Net working cap to sales %23.520.3 116.1%  
Current ratio x1.81.4 129.5%  
Inventory Days Days6764 104.6%  
Debtors Days Days4119 220.9%  
Net fixed assets Rs m12,61012,475 101.1%   
Share capital Rs m239847 28.2%   
"Free" reserves Rs m34,49019,726 174.8%   
Net worth Rs m35,02720,573 170.3%   
Long term debt Rs m1,2126 20,193.3%   
Total assets Rs m54,38739,475 137.8%  
Interest coverage x13.62,612.0 0.5%   
Debt to equity ratio x00 11,860.8%  
Sales to assets ratio x0.90.7 126.2%   
Return on assets %13.68.9 153.1%  
Return on equity %19.217.1 112.7%  
Return on capital %24.926.2 94.7%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,563564 1,163.7%   
Fx outflow Rs m3,0127,429 40.5%   
Net fx Rs m3,552-6,865 -51.7%   
CASH FLOW
From Operations Rs m7,2594,728 153.5%  
From Investments Rs m1,864-1,042 -178.9%  
From Financial Activity Rs m-9,273-3,066 302.4%  
Net Cashflow Rs m-150620 -24.2%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 33.1 10.2 324.5%  
FIIs % 0.0 23.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 15.4 -  
Shareholders   68,381 102,036 67.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS